Allen P. Grunes

Mr. Grunes is an antitrust lawyer in Brownstein’s DC office who advises clients on mergers and acquisitions and represents clients before the federal and state antitrust agencies and Congress.  He has experience in a range of industries including media and entertainment, telecommunications, healthcare, and the high-tech sector.  He previously spent more than a decade at the USDOJ Antitrust Division.

Mr. Grunes is co-author of Big Data and Competition Policy (Oxford University Press).  He currently serves on the Advisory Boards of the American Antitrust Institute and the Institute for Consumer Antitrust Studies at Loyola University Chicago School of Law.  He holds a bachelor’s degree from Dartmouth College, a law degree from Rutgers University, and a master of laws degree from New York University.

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and
Read More

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More

If Private Sector R&D Is the Future, IP Policy Must Catch Up

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely
Read More